Additionally, CD68 positive TAMs were set at a relatively stable platform in PD and SD, which slightly overweighted in PR as a response to ICIs, but transferred in M2 macrophages (Figure 6D), indicating that in patients with favoured clinical outcomes, M1 phenotypes accounted for a large majority of TAMs to exert anti‐tumour effects as a distinguishable biomarker in ICI response prediction. Here, CD68 is linked to neoplasm.